Scynexis Transfers Brexafemme New Drug Application to GSK

MT Newswires Live11-19

Scynexis (SCYX) said Wednesday it has completed the transfer of the new drug application for Brexafemme, or ibrexafungerp, to GSK (GSK).

The transfer allows GSK to begin working with the US Food and Drug Administration on a plan to relaunch Brexafemme for vulvovaginal candidiasis and refractory vulvovaginal candidiasis in the US, Scynexis Chief Executive Officer David Angulo said.

Following a relaunch, Scynexis said it could receive up to $145.5 million in annual net sales milestones as well as low to mid-single-digit royalties on net sales.

Shares of Scynexis were up over 5% in recent Wednesday premarket activity, while GSK was down 0.5%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584941460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584941460","market":"nz","top_or_hot":-1,"title":"Scynexis Transfers Brexafemme New Drug Application to GSK","media":"MT Newswires Live","content":"<html><body><p> Scynexis (SCYX) said Wednesday it has completed the transfer of the new drug application for Brexafemme, or ibrexafungerp, to GSK (GSK).</p><p>The transfer allows GSK to begin working with the US Food and Drug Administration on a plan to relaunch Brexafemme for vulvovaginal candidiasis and refractory vulvovaginal candidiasis in the US, Scynexis Chief Executive Officer David Angulo said.</p><p>Following a relaunch, Scynexis said it could receive up to $145.5 million in annual net sales milestones as well as low to mid-single-digit royalties on net sales.</p><p>Shares of Scynexis were up over 5% in recent Wednesday premarket activity, while GSK was down 0.5%.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scynexis Transfers Brexafemme New Drug Application to GSK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScynexis Transfers Brexafemme New Drug Application to GSK\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-19 21:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Scynexis (SCYX) said Wednesday it has completed the transfer of the new drug application for Brexafemme, or ibrexafungerp, to GSK (GSK).</p><p>The transfer allows GSK to begin working with the US Food and Drug Administration on a plan to relaunch Brexafemme for vulvovaginal candidiasis and refractory vulvovaginal candidiasis in the US, Scynexis Chief Executive Officer David Angulo said.</p><p>Following a relaunch, Scynexis said it could receive up to $145.5 million in annual net sales milestones as well as low to mid-single-digit royalties on net sales.</p><p>Shares of Scynexis were up over 5% in recent Wednesday premarket activity, while GSK was down 0.5%.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2584941460","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584941460","pubTimestamp":1763558663,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Scynexis  said Wednesday it has completed the transfer of the new drug application for Brexafemme, or ibrexafungerp, to GSK .The transfer allows GSK to begin working with the US Food and Drug Administration on a plan to relaunch Brexafemme for vulvovaginal candidiasis and refractory vulvovaginal candidiasis in the US, Scynexis Chief Executive Officer David Angulo said.Following a relaunch, Scynexis said it could receive up to $145.5 million in annual net sales milestones as well as low to mid-single-digit royalties on net sales.Shares of Scynexis were up over 5% in recent Wednesday premarket activity, while GSK was down 0.5%.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克","BK4532":"文艺复兴科技持仓","SCYX":"SCYNEXIS Inc","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","GSK.UK":"葛兰素史克","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Scynexis将Brexafemme新药申请转让给GSK","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":0.6,"GSK":1.5,"SCYX":1},"content_text":"Scynexis (SCYX) said Wednesday it has completed the transfer of the new drug application for Brexafemme, or ibrexafungerp, to GSK (GSK).The transfer allows GSK to begin working with the US Food and Drug Administration on a plan to relaunch Brexafemme for vulvovaginal candidiasis and refractory vulvovaginal candidiasis in the US, Scynexis Chief Executive Officer David Angulo said.Following a relaunch, Scynexis said it could receive up to $145.5 million in annual net sales milestones as well as low to mid-single-digit royalties on net sales.Shares of Scynexis were up over 5% in recent Wednesday premarket activity, while GSK was down 0.5%.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584941460","isCrawlerRequest":true}